Sepsis: The end is just the beginning


Thursday, February 03, 2022 Andy An
Andy An, male with glasses and red checkered shirt

The post was written by Andy An, MD/PhD Candidate, Hancock Lab and edited by Nancy Yang, MSc Candidate, Côté Lab. Andy and Nancy are trainees at the Centre for Blood Research. It originally appeared on the Centre for Blood Research blog in February 2022.

Imagine a cut on your hand gets infected. It gets hot, swollen, painful – but it means your immune system is fighting off that infection. Now imagine that happening throughout your entire body because the infection spread everywhere through your bloodstream. Instead of being protective, your immune system goes into overdrive, resulting in fever, low blood pressure, and life-threatening organ damage. What I described is sepsis, a dysregulated immune response to a systemic infection that results in organ failure. In 2017, ~100,000 Canadians developed sepsis, of which ~16,000 died, and sepsis was involved in 1 in every 5 deaths worldwide1.

Up to now, sepsis research has mainly focused on how to diagnose sepsis earlier and more accurately, or better treatments to improve hospitalization outcomes. However, the long-term effects of sepsis are still poorly understood. Half of all survivors will have long-term consequences, collectively known as “post-sepsis syndrome” (PSS): a constellation of symptoms affecting the brain, muscles, heart, kidneys, lungs, and immune system2. These patients suffer from poorer quality of life and frequent rehospitalizations, with each hospitalization potentially being their last, as a third of survivors will pass away within a year after their sepsis hospitalization2. Furthermore, almost half of previously employed sepsis survivors do not return to work within 6 months after their hospitalization3, commonly experiencing symptoms disruptive to everyday life, such as fatigue, brain fog, and insomnia4.

Despite these debilitating long-term effects, PSS is still poorly understood and researched. In a recent review in EBioMedicine, the Hancock Lab and our collaborators documented the mechanisms and potential therapies of different aspects of PSS4. Central to the development of symptoms is the abnormal immune response that occurs during the onset of sepsis involving both hyperinflammation – called a “cytokine storm” – and immunosuppression. While the initial hyperinflammation can result in organ damage, immunosuppression persists for months, as evidenced by the higher risk of recurrent infections and sepsis after hospital discharge compared to survivors of other hospitalizations. This may be due to a combination of both epigenetic reprogramming of immune cells – non-mutational changes to their DNA that affect gene expression – as well as increases in immunosuppressive cells like regulatory T cells or myeloid-derived suppressor cells. The overactive immune response during sepsis can also damage the brain, resulting in delirium and causing one in five survivors to suffer from poor memory, shorter attention span, and slower mental processing.

In addition to cognitive issues, many sepsis survivors also develop anxiety, depression, and PTSD from their harrowing hospitalization experience and poorer quality of life. Lastly, sepsis survivors have an increased risk of fatal cardiovascular diseases such as stroke, heart attack, and heart failure, which may be caused by dysfunctional mitochondria and oxidative damage during sepsis. Due to such a wide variety of symptoms for PSS, a multi-disciplinary post-sepsis clinic may be able to provide personalized management affecting each sepsis survivor, as well as facilitate recruitment of survivors for observational studies and clinical trials to study PSS and potential treatments.

Interestingly, the COVID-19 pandemic has brought new attention to this phenomenon, as severe COVID-19 is essentially viral sepsis and the symptoms of COVID “long-haulers” are similar to those of sepsis survivors. This has led to heightened scientific interest into long-term COVID symptoms, with the NIH recently granting $470 million to study “long COVID”. The results from this new body of research will hopefully also be applicable to sepsis in general, as well as raise awareness and increase research interest in PSS.

Care for sepsis should not end at hospital discharge. Many sepsis survivors describe feeling lost, scared, and uncared for after surviving their hospitalization, with their primary physicians being ill-equipped at managing their symptoms. Sepsis does not “end” at discharge – it is just the beginning of a long road to recovery for the patient. Thankfully, we are also approaching the “end” of a research period where PSS was neglected. It is the beginning of an era of heightened interest in this phenomenon, spurred by increased sepsis awareness, prevalence, patient advocacy, and the COVID-19 pandemic. With a better understanding of PSS, new management strategies and therapeutic interventions can be developed to make sure that sepsis survivors stay survivors.

This story was originally submitted, in a shorter form, to the 2020-2021 Canadian Blood Services Lay Science Writing Competition, which was organized by the Canadian Blood Services’ Centre for Innovation with support from the UBC Centre for Blood Research. The competition theme was “Challenges 2020”. Canadian Blood Services is proud to partner with the Centre for Blood Research to deliver training and education opportunities for trainees, including the Lay Science Writing Competition. Watch the R.E.D. blog in March 2022 for an announcement of the winners of the 2021-2022 Lay Science Writing Competition. 

Learn more about the sepsis research described in the blog:

  1. Rudd, K. E. et al. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study. Lancet 395, 200–211 (2020).
  2. Mostel, Z. et al. Post-sepsis syndrome – an evolving entity that afflicts survivors of sepsis. Molecular Medicine 26, 6 (2019).
  3. Poulsen, J. B., Møller, K., Kehlet, H. & Perner, A. Long-term physical outcome in patients with septic shock. Acta Anaesthesiol Scand 53, 724–730 (2009).
  4. van der Slikke, E. C., An, A. Y., Hancock, R. E. W. & Bouma, H. R. Exploring the pathophysiology of post-sepsis syndrome to identify therapeutic opportunities. EBioMedicine 61, 103044 (2020).

Canadian Blood Services – Driving world-class innovation

Through discovery, development and applied research, Canadian Blood Services drives world-class innovation in blood transfusion, cellular therapy and transplantation—bringing clarity and insight to an increasingly complex healthcare future. Our dedicated research team and extended network of partners engage in exploratory and applied research to create new knowledge, inform and enhance best practices, contribute to the development of new services and technologies, and build capacity through training and collaboration. Find out more about our research impact. 

The opinions reflected in this post are those of the author and do not necessarily reflect the opinions of Canadian Blood Services nor do they reflect the views of Health Canada or any other funding agency.

ShareTweetShare

Related blog posts


Thursday, March 11, 2021
Dr. Geraldine Walsh

The Centre for Innovation is delighted to announce the winners of the 2020-2021 Canadian Blood Services Lay Science Writing Competition. Read on to find out who won!


Tuesday, March 23, 2021
Polina Petlitsyna

We are delighted to publish the entries that were awarded joint first place in this year’s Lay Science Writing Competition. Read on for Polina Petlitsyna’s engaging entry about her work as a summer student at the Centre for Blood Research and the importance of good communication to build trust in science.


Tuesday, March 23, 2021
Melina Messing

We are delighted to publish the entries that were awarded joint first place in this year’s Lay Science Writing Competition. Read on for Melina Messing’s sobering but ultimately hopeful entry describing her experiences as a immunology researcher during the pandemic.